#USA #Los Angeles #Healthcare Innovation #Sensydia #Cardiac Performance System

Sensydia's Groundbreaking Funding for Cardiac Solutions

In a recent milestone achievement, Sensydia, a pioneering medical technology company specializing in non-invasive cardiac assessments, has secured more than $6 million in an oversubscribed funding round. This important financing is driven by Colle Capital Partners, with substantial support from Orlando Health Ventures. The funds will play a crucial role in advancing Sensydia’s innovative Cardiac Performance System (CPS™) and completing its ongoing ACOUSTIC‑1 clinical study, which is aimed at receiving FDA authorization.

The CPS™ is designed to deliver accurate pulmonary pressure assessments in various clinical environments, while eliminating the need for invasive catheterization procedures. This capability is particularly vital for clinicians, as it allows for timely and precise evaluations of patients experiencing heart failure or pulmonary hypertension. The CPS™ utilizes sophisticated artificial intelligence (AI) algorithms to analyze both acoustic and electrical cardiac signals, providing clinicians with essential data to inform their diagnostic and treatment decisions.

As of July 2026, a new Category III CPT® code (1036T) was introduced, supporting non-invasive hemodynamic assessments based on methodologies that resonate closely with those utilized by CPS™. This validation signals a shift toward greater adoption of non-invasive technologies in the healthcare industry, emphasizing the importance of acquiring accurate and actionable cardiac metrics at the point of care.

Bill Hawkins, the former Chairman and CEO of Medtronic and an advisor to Sensydia, noted, "The most important medical technology companies create categories rather than compete in them. Sensydia has the makings of one a new way to bring pressure information to the point of care, and the foundation to scale it."

Reflecting on the technology’s implications, Anthony Arnold, CEO of Sensydia, stated, "Cardiologists treating heart failure need the right metric, in the right place, at the right time. We built CPS to give clinicians objective pressure information in the office, where therapy decisions are made."

The collaboration with Colle Capital and Orlando Health Ventures positions Sensydia to expedite the market introduction of CPS™, ultimately aiming to alleviate the burdens faced by patients suffering from heart failure. Victoria Grace, Founding Partner of Colle Capital Partners, highlighted the unique attributes of CPS™, emphasizing that it is based on catheterization data—the clinical gold standard for cardiac assessments—collected at a scale that few companies attempt. This gives them confidence in Sensydia’s vision and strategy.

A New Era in Cardiac Care

Sensydia’s CPS™ aims to provide healthcare professionals with rapid, safe, and accurate assessments of hemodynamic function, thereby enhancing the diagnosis and overall management of heart conditions such as heart failure and pulmonary hypertension. The technology has already gained recognition, receiving FDA Breakthrough Device designation, and boasts a regulatory history that includes achieving FDA 510(k) clearance in 2018 for algorithms pertaining to non-invasive ejection fraction measurement.

As the healthcare landscape continues to evolve, Sensydia's commitment to advancing innovative medical technologies represents a beacon of hope for patients and healthcare providers alike. By ensuring that accurate cardiac assessments are accessible and convenient, the CPS™ stands to improve patient outcomes significantly.

Interested stakeholders can learn more about Sensydia and the CPS™ at Sensydia’s official website. This development is a compelling illustration of how innovative funding and technology can reshape the healthcare industry, enhancing diagnostic capabilities and improving patient care pathways.

As Sensydia prepares for its next steps, the journey of this promising technology is just beginning and will be closely watched by healthcare professionals and investors alike. The eventual launch of the CPS™ into the market signals a progressive shift in cardiac care, offering clinicians the tools they need to provide superior care based on accuracy and timely insights.